FULCRUM THERAPEUTICS, INC. Increase (Decrease) in Deferred Revenue
FULCRUM THERAPEUTICS, INC. (FULC) reported Increase (Decrease) in Deferred Revenue of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2025-02-25
- FULCRUM THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2024-12-31 was $0.00.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2024-09-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2024-06-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2024-03-31 was $0.00.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2024 was $0.00.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2023 was -$934.00K.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2022 was -$3.78M.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2021 was -$13.17M, a 267.11% decline from fiscal 2020.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | -$334.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $0.00 10-Q · filed 2024-07-31 | -$334.00K derived: sum of 3 quarters · filed 2025-02-25 | -$513.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-13 | -$334.00K derived: sum of 2 quarters · filed 2025-02-25 | -$513.00K derived: sum of 3 quarters · filed 2025-02-25 | -$737.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-12-31 | -$334.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$513.00K derived: sum of 2 quarters · filed 2025-02-25 | -$737.00K derived: sum of 3 quarters · filed 2025-02-25 | -$934.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | -$179.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$403.00K derived: sum of 2 quarters · filed 2024-11-13 | -$600.00K 10-Q · filed 2024-11-13 | -$1.05M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$224.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | -$421.00K 10-Q · filed 2024-07-31 | -$876.00K derived: sum of 3 quarters · filed 2024-07-31 | -$1.27M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | -$197.00K 10-Q · filed 2024-05-13 | -$652.00K derived: sum of 2 quarters · filed 2024-05-13 | -$1.04M derived: sum of 3 quarters · filed 2024-05-13 | -$2.18M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$455.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$848.00K derived: sum of 2 quarters · filed 2024-02-27 | -$1.99M derived: sum of 3 quarters · filed 2024-02-27 | -$3.78M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$393.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$1.53M derived: sum of 2 quarters · filed 2023-11-07 | -$3.32M 10-Q · filed 2023-11-07 | -$4.74M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.93M 10-Q · filed 2023-08-03 | -$4.35M derived: sum of 3 quarters · filed 2023-08-03 | -$8.12M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$1.79M 10-Q · filed 2023-05-15 | -$3.21M derived: sum of 2 quarters · filed 2023-06-26 | -$6.98M derived: sum of 3 quarters · filed 2023-06-26 | -$10.70M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | -$1.42M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | -$5.19M derived: sum of 2 quarters · filed 2023-06-26 | -$8.91M derived: sum of 3 quarters · filed 2023-06-26 | -$13.17M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | -$3.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$7.49M derived: sum of 2 quarters · filed 2022-11-08 | -$11.75M 10-Q · filed 2022-11-08 | -$13.44M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-06-30 | -$3.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$7.98M 10-Q · filed 2022-08-11 | -$9.67M derived: sum of 3 quarters · filed 2023-06-26 | $1.57M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-03-31 | -$4.26M 10-Q · filed 2022-05-09 | -$5.95M derived: sum of 2 quarters · filed 2023-06-26 | $5.29M derived: sum of 3 quarters · filed 2023-06-26 | $4.05M derived: sum of 4 quarters · filed 2023-06-26 |
| 2020-12-31 | -$1.69M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $9.55M derived: sum of 2 quarters · filed 2023-06-26 | $8.31M derived: sum of 3 quarters · filed 2023-06-26 | $7.88M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $11.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $10.00M derived: sum of 2 quarters · filed 2021-11-04 | $9.57M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$1.67M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$425.00K 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $10.00M 10-K/A · filed 2023-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |